Mats Blom
Director/Board Member bei ALTAMIRA THERAPEUTICS LTD.
Vermögen: 2 Mio $ am 31.03.2024
Profil
Mr. Mats Blom is an Independent Director at Egetis Therapeutics AB, a Chief Financial Officer at NorthSea Therapeutics BV, an Independent Director at Hansa Biopharma AB and an Independent Non-Executive Director at Altamira Therapeutics Ltd.
He is on the Board of Directors at Egetis Therapeutics AB, Hansa Biopharma AB, Altamira Therapeutics Ltd., Auris Medical AG and Pephexia Therapeutics ApS.
Mr. Blom was previously employed as a Chief Financial Officer by Modus Therapeutics AB, an Independent Non-Executive Director by Auris Medical Holding AG /Old/, a Chief Financial Officer & Executive Vice President by Zealand Pharma A/S, a Chief Financial Officer by Swedish Orphan International Holding AB, a Chief Financial Officer by Anoto Group AB, a CFO & Vice President-Business Development by Active Biotech AB, and a Chairman by Immedica Pharma AB.
He received his undergraduate degree from the University of Lund and an MBA from the Instituto de Estudios Superiores de la Empresa.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
EGETIS THERAPEUTICS AB
1,00% | 31.12.2022 | 2 934 762 ( 1,00% ) | 2 Mio $ | 31.03.2024 |
HANSA BIOPHARMA AB
0,00% | 31.12.2022 | 1 000 ( 0,00% ) | 2 722 $ | 31.03.2024 |
29.03.2024 | 0 ( -.--% ) | - $ | 31.03.2024 |
Aktive Positionen von Mats Blom
Unternehmen | Position | Beginn |
---|---|---|
ALTAMIRA THERAPEUTICS LTD. | Director/Board Member | 01.04.2017 |
HANSA BIOPHARMA AB | Director/Board Member | 22.05.2019 |
EGETIS THERAPEUTICS AB | Director/Board Member | 01.04.2021 |
Auris Medical AG
Auris Medical AG Medical SpecialtiesHealth Technology Auris Medical AG manufactures electronic devices for ear disorders. It develops novel pharmaceutical therapies to protect hearing and to silence tinnitus. The company was founded by Thomas Meyer in April 2003 and is headquartered in Basel, Switzerland. | Director/Board Member | - |
NorthSea Therapeutics BV
NorthSea Therapeutics BV BiotechnologyHealth Technology NorthSea Therapeutics BV operates as a biotechnology company. It develops oral, structurally engineered fatty acid therapeutics. The company was founded by Hilde H. Steineger and David A. Fraser and is headquartered in Naarden, the Netherlands. | Director of Finance/CFO | 01.09.2019 |
Pephexia Therapeutics ApS | Director/Board Member | - |
Ehemalige bekannte Positionen von Mats Blom
Unternehmen | Position | Ende |
---|---|---|
Modus Therapeutics AB
Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden. | Director of Finance/CFO | 15.03.2021 |
ZEALAND PHARMA A/S | Director of Finance/CFO | 31.03.2019 |
Swedish Orphan International Holding AB
Swedish Orphan International Holding AB Pharmaceuticals: MajorHealth Technology Swedish Orphan International Holding AB is an international group with its head office in Stockholm, Sweden. The original company was formed in 1988, taking as its starting point the US Orphan Drug Act of 1983. In 2004, the company was acquired by a consortium consisting of Investor Growth Capital, Skandia Investment and the management of Swedish Orphan International AB. The operating companies are Swedish Orphan International and its subsidiaries in Europe and Japan. The organizational structure is primarily based on a logistical perspective. In order to reach patients in emergency situations, regardless of where they are, it needs an extensive organization with strong local roots and the ability to see things in a larger perspective. The better and broader its partnerships, the more effectively the firm can work and the greater the synergies that it can achieve between the various markets. | Director of Finance/CFO | 03.06.2010 |
░░░░░ ░░░░░ ░░ | ░░░░░░░░ ░░ ░░░░░░░░ ░ ░░░ ░░░ | ░░░░░░░░░░ |
░░░░░░ ░░░░░░░ ░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | ░░░░░░░░░░ |
Ausbildung von Mats Blom
University of Lund | Undergraduate Degree |
Instituto de Estudios Superiores de la Empresa | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 6 |
---|---|
ANOTO GROUP AB | Electronic Technology |
ACTIVE BIOTECH AB | Health Technology |
ZEALAND PHARMA A/S | Health Technology |
HANSA BIOPHARMA AB | Health Technology |
EGETIS THERAPEUTICS AB | Health Technology |
ALTAMIRA THERAPEUTICS LTD. | Health Technology |
Private Unternehmen | 7 |
---|---|
Swedish Orphan International Holding AB
Swedish Orphan International Holding AB Pharmaceuticals: MajorHealth Technology Swedish Orphan International Holding AB is an international group with its head office in Stockholm, Sweden. The original company was formed in 1988, taking as its starting point the US Orphan Drug Act of 1983. In 2004, the company was acquired by a consortium consisting of Investor Growth Capital, Skandia Investment and the management of Swedish Orphan International AB. The operating companies are Swedish Orphan International and its subsidiaries in Europe and Japan. The organizational structure is primarily based on a logistical perspective. In order to reach patients in emergency situations, regardless of where they are, it needs an extensive organization with strong local roots and the ability to see things in a larger perspective. The better and broader its partnerships, the more effectively the firm can work and the greater the synergies that it can achieve between the various markets. | Health Technology |
Immedica Pharma AB
Immedica Pharma AB Medical DistributorsDistribution Services Immedica Pharma AB provides know-how and access of specialty care medicine and products. It also provides information on regulatory and medical affairs and product distribution. The company is headquartered in Stockholm, Sweden. | Distribution Services |
Modus Therapeutics AB
Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden. | Health Technology |
Auris Medical Holding AG /Old/
Auris Medical Holding AG /Old/ Medical SpecialtiesHealth Technology Auris Medical Holding AG engages in the research, development, and commercialization of pharmaceutical products for inner ear disorders. Its products portfolio targets to treat tinnitus, Menière's disease, and hearing loss. The company was founded by Thomas Meyer on April 1, 1998 and is headquartered in Zug, Switzerland. | Health Technology |
NorthSea Therapeutics BV
NorthSea Therapeutics BV BiotechnologyHealth Technology NorthSea Therapeutics BV operates as a biotechnology company. It develops oral, structurally engineered fatty acid therapeutics. The company was founded by Hilde H. Steineger and David A. Fraser and is headquartered in Naarden, the Netherlands. | Health Technology |
Pephexia Therapeutics ApS | |
Auris Medical AG
Auris Medical AG Medical SpecialtiesHealth Technology Auris Medical AG manufactures electronic devices for ear disorders. It develops novel pharmaceutical therapies to protect hearing and to silence tinnitus. The company was founded by Thomas Meyer in April 2003 and is headquartered in Basel, Switzerland. | Health Technology |